Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | UNG | P13051 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29846591 | 1.00 | ALDH1A1 (0.48) | ALDH1A1HDAC4HDAC2HDAC8UNG | |
| SCHEMBL6848985 | 0.87 | ALDH1A1 (0.48) | ALDH1A1UNGCYP2A6SRCNPC1 | |
| SCHEMBL1283463 | 0.84 | CYP3A4 (0.47) | ALDH1A1SRCNPC1RAB9AL3MBTL1 | |
| SCHEMBL12517077 | 0.84 | MAOA (0.41) | ALDH1A1HDAC4HDAC2HDAC8UNG | |
| SCHEMBL15352523 | 0.83 | ALDH1A1 (0.45) | ALDH1A1UNGCYP2A6SRCNPC1 | |
| SCHEMBL3509619 | 0.83 | UNG (0.46) | ALDH1A1HDAC4HDAC2HDAC8UNG | |
| SCHEMBL1111336 | 0.83 | ALDH1A1 (0.45) | ALDH1A1UNGACHECYP2A6SRC | |
| SCHEMBL6854509 | 0.83 | ESR1 (0.52) | ALDH1A1UNGCYP2A6SRCTRIM24 | |
| SCHEMBL5778960 | 0.83 | ALDH1A1 (0.45) | ALDH1A1UNGCYP2A6SRCNPC1 | |
| SCHEMBL5433181 | 0.82 | HDAC8 (0.45) | ALDH1A1HDAC4HDAC2HDAC8ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 506 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109762025-A | A kind of nitric oxidereductase analogies and preparation method thereof | 湖南科技大学 | 2019-05-17 | — | — | CN | claimed |
| EP-2411564-B1 | ELECTROCHEMICAL PROCESS FOR PRODUCING 3-TERT-BUTYLBENZALDEHYDE-DIMETHYLACETAL | BASF SE (DE) | 2017-05-10 | — | — | EP | claimed |
| CN-103119014-B | Produce the method with 2-methyl-3-(4-tert-butyl-phenyl) propionic aldehyde of high contraposition isomeric purities | BASF SE (DE) | 2016-01-20 | — | — | CN | claimed |
| EP-2616424-B1 | METHOD FOR PRODUCING 2-METHYL-3-(4-TERT-BUTYLPHENYL)-PROPANAL HAVING HIGH PARA-ISOMER PURITY | BASF SE (DE) | 2015-08-26 | — | — | EP | claimed |
| CN-102365393-B | Electrochemical method for producing 3 tert.-butyl benzaldehyde- dimethylacetal | BASF SE (DE) | 2014-10-29 | — | — | CN | claimed |
| US-8629304-B2 | Electrochemical method for producing 3-tert-butylbenzaldehyde dimethyl acetal | BASF SE (DE) | 2014-01-14 | — | — | US | claimed |
| US-8614358-B2 | Process for preparing 2-methyl-3-(4-tert-butylphenyl)propanal with high para-isomer purity | BASF SE (DE) | 2013-12-24 | — | — | US | claimed |
| EP-2616424-A1 | METHOD FOR PRODUCING 2-METHYL-3-(4-TERT-BUTYLPHENYL)-PROPANAL HAVING HIGH PARA-ISOMER PURITY | BASF SE (DE) | 2013-07-24 | — | — | EP | claimed |
| CN-103119014-A | Method for producing 2-methyl-3-(4-tert-butylphenyl)-propanal having high para-isomer purity | BASF SE | 2013-05-22 | — | — | CN | claimed |
| US-20120071696-A1 | PROCESS FOR PREPARING 2-METHYL-3-(4-TERT-BUTYLPHENYL)PROPANAL WITH HIGH PARA-ISOMER PURITY | BASF SE (DE) | 2012-03-22 | — | — | US | claimed |
| WO-2012034930-A1 | METHOD FOR PRODUCING 2-METHYL-3-(4-TERT-BUTYLPHENYL)-PROPANAL HAVING HIGH PARA-ISOMER PURITY | BASF SE (DE) | 2012-03-22 | — | — | WO | claimed |
| CN-102365393-A | Electrochemical method for producing 3 tert.-butyl benzaldehyde- dimethylacetal | BASF SE | 2012-02-29 | — | — | CN | claimed |
| EP-2411564-A1 | ELECTROCHEMICAL METHOD FOR PRODUCING 3 TERT.-BUTYL BENZALDEHYDE- DIMETHYLACETAL | BASF SE (DE) | 2012-02-01 | — | — | EP | claimed |
| US-20120016162-A1 | ELECTROCHEMICAL METHOD FOR PRODUCING 3-TERT-BUTYLBENZALDEHYDE DIMETHYL ACETAL | BASF SE (DE) | 2012-01-19 | — | — | US | claimed |
| WO-2010108874-A1 | ELECTROCHEMICAL METHOD FOR PRODUCING 3 TERT.-BUTYL BENZALDEHYDE- DIMETHYLACETAL | BASF SE (DE) | 2010-09-30 | — | — | WO | claimed |
| US-6723883-B1 | REACTING A BENZALDEHYDE COMPOUND WITH AN ALKANALDEHYDE; CASCADE SYSTEM | BASF AKTIENGESELLSCHAFT (DE) | 2004-04-20 | — | — | US | claimed |
| EP-1390336-A1 | METHOD FOR PRODUCING AROMATIC ALDEHYDES AND KETONES BY THE CATALYTIC OXIDATION OF ALKYL-AROMATIC COMPOUNDS | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2004-02-25 | — | — | EP | claimed |
| EP-1220824-B1 | CONTINUOUS METHOD FOR PRODUCTION OF CINNAMALDEHYDE AND DIHYDROCINNAMALDEHYDE DERIVATIVES | BASF AG (DE) | 2004-02-11 | — | — | EP | claimed |
| WO-2002096849-A1 | METHOD FOR PRODUCING AROMATIC ALDEHYDES AND KETONES BY THE CATALYTIC OXIDATION OF ALKYL-AROMATIC COMPOUNDS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2002-12-05 | — | — | WO | claimed |
| JP-2238097-A | — | — | None | — | — | JP | disclosed |
| CN-122063106-A | Method, reagent and sensing film for detecting unsymmetrical dimethylhydrazine based on 2, 4-dinitrobenzaldehyde chromogenic reaction | 中国人民解放军63921部队 | 2026-05-19 | — | — | CN | disclosed |
| EP-4720036-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | 16380026 Canada Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720037-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | 16380026 Canada Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| EP-3773573-B1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC INC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| EP-4103557-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-12-23 | — | — | US | disclosed |
| EP-4180415-B1 | ALIPHATIC DIAMINE ISOMERIZATION METHOD, DIISOCYANATE PRODUCTION METHOD, POLYURETHANE PRODUCTION METHOD, AND POLYURETHANE | MITSUBISHI GAS CHEMICAL CO (JP) | 2025-11-26 | — | — | EP | disclosed |
| EP-4384165-B1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-09 | — | — | EP | disclosed |
| CN-119504685-A | Benzopyran flavonoid compound, preparation method and application thereof, and pharmaceutical preparation | 南开大学 | 2025-02-25 | — | — | CN | disclosed |
| US-12221416-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| WO-2024243692-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2024-12-05 | — | — | WO | disclosed |
| CN-115066422-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240299365-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-12 | — | — | US | disclosed |
| US-20240294475-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2024-09-05 | — | — | US | disclosed |
| EP-4384165-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | Janssen Pharmaceutica NV (BE) | 2024-06-19 | — | — | EP | disclosed |
| CN-118076351-A | Monoacylglycerol lipase modulators for autism spectrum disorders | 詹森药业有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11974987-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-07 | — | — | US | disclosed |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | LG CHEM, LTD. (KR) | 2024-03-28 | — | — | US | disclosed |
| CN-117603088-A | Aromatic aldehyde Schiff base based on amino acid ethyl ester and application thereof in asymmetric alkylation | 广东工业大学 | 2024-02-27 | — | — | CN | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-01-11 | — | — | US | disclosed |
| US-11834424-B2 | Compounds useful as chaperone-mediated autophagy modulators | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230382902-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-30 | — | — | US | disclosed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230355617-A1 | SMALL MOLECULE INHIBITORS OF LEMUR TYROSINE KINASE 3 | THE UNIVERSITY OF SUSSEX (GB) | 2023-11-09 | — | — | US | disclosed |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-11795148-B2 | Compounds and methods for inhibiting CYP26 enzymes | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2023-10-24 | — | — | US | disclosed |
| US-11795148-B2 | Compounds and methods for inhibiting CYP26 enzymes | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2023-10-24 | — | — | US | disclosed |
| US-20230303512-A1 | MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4242213-A1 | BORONIC ACID COMPOUND | Lg Chem, Ltd. (KR) | 2023-09-13 | — | — | EP | disclosed |
| US-11739080-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | FORESEE PHARMACEUTICALS USA, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| CN-116670143-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4225447-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230250047-A1 | METHOD FOR ISOMERIZING ALIPHATIC DIAMINE, METHOD FOR PRODUCING DIISOCYANATE, METHOD FOR PRODUCING POLYURETHANE, AND POLYURETHANE | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2023-08-10 | — | — | US | disclosed |
| CN-111378084-B | Polymer and hardmask composition and method of forming pattern | 三星SDI株式会社 | 2023-08-08 | — | — | CN | disclosed |
| CN-116568310-A | Boric acid compounds | 株式会社LG化学 | 2023-08-08 | — | — | CN | disclosed |
| US-11708359-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-25 | — | — | US | disclosed |
| US-11697650-B2 | Compounds having tetrahydroindolizine-1-carboxamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| EP-4180415-A1 | ALIPHATIC DIAMINE ISOMERIZATION METHOD, DIISOCYANATE PRODUCTION METHOD, POLYURETHANE PRODUCTION METHOD, AND POLYURETHANE | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2023-05-17 | — | — | EP | disclosed |
| US-11649218-B2 | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230117611-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-20 | — | — | US | disclosed |
| US-20230121700-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | SCRIPPS RESEARCH INST (US) | 2023-03-09 | — | — | US | disclosed |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | SCRIPPS RESEARCH INST (US) | 2023-03-09 | — | — | US | disclosed |
| US-20230075221-A1 | SUBSTITUTED 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVE AND PREPARATION METHOD, HERBICIDAL COMPOSITION AND APPLICATION THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2023-03-09 | — | — | US | disclosed |
| CN-115768742-A | Method for isomerizing aliphatic diamine, method for producing diisocyanate, method for producing polyurethane, and polyurethane | 三菱瓦斯化学株式会社 | 2023-03-07 | — | — | CN | disclosed |
| US-20230055237-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2023-02-23 | — | — | US | disclosed |
| US-20230055237-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2023-02-23 | — | — | US | disclosed |
| WO-2023019094-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-16 | — | — | WO | disclosed |
| EP-4103557-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-12-21 | — | — | EP | disclosed |
| CN-111253236-B | Preparation method of high-quality para-lilial | 宿迁科思化学有限公司 | 2022-11-18 | — | — | CN | disclosed |
| US-20220340529-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220304307-A1 | SYNERGISTIC MIXTURES FOR ARTHROPOD TOXICITY AND REPELLENCY | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2022-09-29 | — | — | US | disclosed |
| CN-115066422-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| US-11358933-B2 | Compounds and methods for inhibiting CYP26 enzymes | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2022-06-14 | — | — | US | disclosed |
| CN-111517902-B | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2022-06-14 | — | — | CN | disclosed |
| US-20220162235-A1 | LUMINESCENT SILAFLUORENE AND GERMAFLUORENE COMPOUNDS | NATIONAL SCIENCE FOUNDATION | 2022-05-26 | — | — | US | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| US-11325930-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11306084-B2 | Integrin antagonists | SAINT LOUIS UNIVERSITY (US) | 2022-04-19 | — | — | US | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022046999-A1 | MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-03 | — | — | WO | disclosed |
| US-11247972-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-11220570-B2 | Polymer, hardmask composition, and method of forming patterns | SAMSUNG SDI CO., LTD. (KR) | 2022-01-11 | — | — | US | disclosed |
| EP-3917516-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | Flatley Discovery Lab, LLC (US) | 2021-12-08 | — | — | EP | disclosed |
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AMGEN INC. (US) | 2021-12-07 | — | — | US | disclosed |
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | disclosed |
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | MORPHIC THERAPEUTIC, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | MORPHIC THERAPEUTIC, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2021226276-A2 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| CN-113613649-A | Compounds and methods for treating cystic fibrosis | 弗拉特利发现实验室有限责任公司 | 2021-11-05 | — | — | CN | disclosed |
| CN-111875610-B | Copper porphyrin catalyst and preparation and application of composite material thereof | 湖南科技大学 | 2021-08-31 | — | — | CN | disclosed |
| US-20210253565-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-19 | — | — | US | disclosed |
| WO-2021160602-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-19 | — | — | WO | disclosed |
| US-20210246118-A1 | SUBSTITUTED PYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2021-08-12 | — | — | US | disclosed |
| EP-3523277-B1 | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | ABBVIE OVERSEAS SARL (LU) | 2021-06-30 | — | — | EP | disclosed |
| EP-3523293-B1 | SUBSTITUTED PYRROLIDINES AND THEIR USE IN THE TREATMENT OF CYSTIC FIIBROSIS | ABBVIE OVERSEAS SARL (LU) | 2021-06-16 | — | — | EP | disclosed |
| US-20210147454-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210107870-A1 | Compounds and Methods for Inhibiting CYP26 Enzymes | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2021-04-15 | — | — | US | disclosed |
| US-20210061831-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2021-03-04 | — | — | US | disclosed |
| EP-3773573-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | Morphic Therapeutic, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2021022059-A1 | SYNERGISTIC MIXTURES FOR ARTHROPOD TOXICITY AND REPELLENCY | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-02-04 | — | — | WO | disclosed |
| CN-112312910-A | Human integrin alpha 4 beta 7 antagonists | 莫菲克医疗股份有限公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-107428674-B | Method for isomerizing 1,3, 3-trimethyl-1- (aminomethyl) aminocyclohexane | 三菱瓦斯化学株式会社 | 2021-01-29 | — | — | CN | disclosed |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200369609-A1 | Compounds and Methods for Inhibiting CYP26 Enzymes | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2020-11-26 | — | — | US | disclosed |
| CN-111875610-A | Copper porphyrin catalyst and preparation and application of composite material thereof | 湖南科技大学 | 2020-11-03 | — | — | CN | disclosed |
| US-20200308161-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2020-10-01 | — | — | US | disclosed |
| CN-108047089-B | Preparation method of 4-tert-butyl phthalonitrile | 湖南道仕医药科技有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-10759756-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759756-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-08-18 | — | — | US | disclosed |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-08-18 | — | — | US | disclosed |
| CN-111517902-A | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2020-08-11 | — | — | CN | disclosed |
| WO-2020155595-A1 | AEROBIC OXIDATION SYSTEM CONTAINING SULFINIC ACID, SULFONIC ACID OR DERIVATIVES THEREOF AND PHOTOCATALYTIC OXIDATION METHOD THEREFOR | 清华大学 | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160010-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160010-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20200223803-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2020-07-16 | — | — | US | disclosed |
| CN-107406365-B | Process for the isomerization of diaminodicyclohexylmethane | 三菱瓦斯化学株式会社 | 2020-07-14 | — | — | CN | disclosed |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| CN-111378084-A | Polymer and hardmask composition and method of forming a pattern | 三星SDI株式会社 | 2020-07-07 | — | — | CN | disclosed |
| US-20200207902-A1 | POLYMER, HARDMASK COMPOSITION, AND METHOD OF FORMING PATTERNS | SAMSUNG SDI CO., LTD. (KR) | 2020-07-02 | — | — | US | disclosed |
| CN-111253236-A | Preparation method of high-quality para-lilial | 宿迁科思化学有限公司 | 2020-06-09 | — | — | CN | disclosed |
| US-10675358-B2 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-06-09 | — | — | US | disclosed |
| US-10647683-B2 | Hsp70 modulators and methods for making and using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-05-12 | — | — | US | disclosed |
| CN-107406367-B | Process for the isomerization of cyclohexanediamine | 三菱瓦斯化学株式会社 | 2020-04-24 | — | — | CN | disclosed |
| US-10544104-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | University of Washington Through its Center for Co (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190345155-A1 | INTEGRIN ANTAGONISTS | Indalo Therapeutics, Inc. | 2019-11-14 | — | — | US | disclosed |
| EP-3562826-A1 | INTEGRIN ANTAGONISTS | Saint Louis University (US) | 2019-11-06 | — | — | EP | disclosed |
| WO-2019200202-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2019200202-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20190315687-A1 | Substituted Pyrrolidines and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2019-10-17 | — | — | US | disclosed |
| US-20190290647-A1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-10399940-B2 | Substituted pyrrolidines and methods of use | ABBVIE S.Á.R.L. (LU) | 2019-09-03 | — | — | US | disclosed |
| EP-3523293-A1 | SUBSTITUTED PYRROLIDINES AND THEIR USE IN THE TREATMENT OF CYSTIC FIIBROSIS | Abbvie S.a.r.l. (LU) | 2019-08-14 | — | — | EP | disclosed |
| US-20190241526-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2019-08-08 | — | — | US | disclosed |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| CN-110036009-A | Substituted pyrrolidines and their use in the treatment of cystic fibrosis | 艾伯维公司 | 2019-07-19 | — | — | CN | disclosed |
| CN-110035993-A | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | 艾伯维公司 | 2019-07-19 | — | — | CN | disclosed |
| US-10344016-B2 | Bromotriazole intermediates | AMGEN INC. (US) | 2019-07-09 | — | — | US | disclosed |
| WO-2019113693-A1 | COMPOUNDS AND METHODS FOR INHIBITING CYP26 ENZYMES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2019-06-20 | — | — | WO | disclosed |
| US-10316017-B2 | COT modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| CN-109762025-A | A kind of nitric oxidereductase analogies and preparation method thereof | 湖南科技大学 | 2019-05-17 | — | — | CN | disclosed |
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| US-20190076547-A1 | ANTIBODY ADJUVANT CONJUGATES | BOLT BIOTHERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
| US-20180369196-A1 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2018-12-27 | — | — | US | disclosed |
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2018-08-09 | — | — | US | disclosed |
| WO-2018132268-A1 | INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2018-07-19 | — | — | WO | disclosed |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180170883-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2018-06-21 | — | — | US | disclosed |
| US-20180170883-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2018-06-21 | — | — | US | disclosed |
| US-9988369-B2 | Heterocyclic triazole compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9981910-B2 | Substituted pyrrolidines and methods of use | ABBVIE S.Á.R.L. (LU) | 2018-05-29 | — | — | US | disclosed |
| US-9955689-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| US-20180099932-A1 | Substituted Pyrrolidines and Methods of Use | GALAPAGOS NV (BE) | 2018-04-12 | — | — | US | disclosed |
| WO-2018065962-A1 | SUBSTITUTED PYRROLIDINES AND THEIR USE IN THE TREATMENT OF CYSTIC FIIBROSIS | AbbVie S.à.r.l. (LU) | 2018-04-12 | — | — | WO | disclosed |
| US-20180099931-A1 | Substituted Pyrrolidines and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2018-04-12 | — | — | US | disclosed |
| US-9894901-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-20 | — | — | US | disclosed |
| US-9878987-B2 | HSP70 modulators and methods for making and using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878987-B2 | HSP70 modulators and methods for making and using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-01-30 | — | — | US | disclosed |
| US-20180022709-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-01-25 | — | — | US | disclosed |
| US-20180022709-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-01-25 | — | — | US | disclosed |
| US-9872493-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-01-23 | — | — | US | disclosed |
| US-9868721-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868721-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9845310-B2 | Intermediates for preparing triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845310-B2 | Intermediates for preparing triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-11-09 | — | — | US | disclosed |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-9783501-B2 | Substituted quinolines as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170281625-A1 | METHODS OF TREATING HEART FAILURE | AMGEN INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281625-A1 | METHODS OF TREATING HEART FAILURE | AMGEN INC. | 2017-10-05 | — | — | US | disclosed |
| US-9765037-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765037-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2017-09-19 | — | — | US | disclosed |
| US-9751864-B2 | Methods for preparing triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751864-B2 | Methods for preparing triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9745286-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170233352-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2017-08-17 | — | — | US | disclosed |
| US-20170233352-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2017-08-17 | — | — | US | disclosed |
| EP-3204382-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2017-08-16 | — | — | EP | disclosed |
| US-9732078-B2 | Therapeutic use of imidazopyridine derivatives | SANOFI (FR) | 2017-08-15 | — | — | US | disclosed |
| US-9732078-B2 | Therapeutic use of imidazopyridine derivatives | SANOFI (FR) | 2017-08-15 | — | — | US | disclosed |
| US-20170226131-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9670212-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9656997-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656997-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656998-B2 | Intermediates for preparing triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656998-B2 | Intermediates for preparing triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2411564-B1 | ELECTROCHEMICAL PROCESS FOR PRODUCING 3-TERT-BUTYLBENZALDEHYDE-DIMETHYLACETAL | BASF SE (DE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2411564-B1 | ELECTROCHEMICAL PROCESS FOR PRODUCING 3-TERT-BUTYLBENZALDEHYDE-DIMETHYLACETAL | BASF SE (DE) | 2017-05-10 | — | — | EP | disclosed |
| US-20170107205-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170107206-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-04-20 | — | — | US | disclosed |
| US-9573936-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573936-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20170042871-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044131-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170042897-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170042872-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170042872-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170042897-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044131-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170035730-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2017-02-09 | — | — | US | disclosed |
| US-20170035730-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2017-02-09 | — | — | US | disclosed |
| US-20170035730-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2017-02-09 | — | — | US | disclosed |
| US-20170036980-A1 | COPPER CATALYZED [18F]FLUORINATION OF IODONIUM SALTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-02-09 | — | — | US | disclosed |
| US-20170036980-A1 | COPPER CATALYZED [18F]FLUORINATION OF IODONIUM SALTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-02-09 | — | — | US | disclosed |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170035744-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170035744-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| US-9522145-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160340336-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2016-11-24 | — | — | US | disclosed |
| US-9452164-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| US-20160143898-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160122337-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2016-05-05 | — | — | US | disclosed |
| CN-105555754-A | Isomerization method for bis(amino-methyl)cyclohexane | MITSUBISHI GAS CHEMICAL CO | 2016-05-04 | — | — | CN | disclosed |
| WO-2016057500-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-9290515-B2 | Cephem derivative having catechol group | SHIONOGI & CO., LTD (JP) | 2016-03-22 | — | — | US | disclosed |
| US-9266878-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD CALISTOGA LLC (US) | 2016-02-23 | — | — | US | disclosed |
| CN-103119014-B | Produce the method with 2-methyl-3-(4-tert-butyl-phenyl) propionic aldehyde of high contraposition isomeric purities | BASF SE (DE) | 2016-01-20 | — | — | CN | disclosed |
| EP-2837617-B1 | Process for producing alicyclic aldehydes | MITSUBISHI GAS CHEMICAL CO (JP) | 2015-12-23 | — | — | EP | disclosed |
| US-20150336945-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-26 | — | — | US | disclosed |
| US-20150305332-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-29 | — | — | US | disclosed |
| WO-2015161108-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015161108-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-10-22 | — | — | WO | disclosed |
| US-20150289506-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20150289512-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20150282482-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-08 | — | — | US | disclosed |
| EP-2926660-A1 | METHOD FOR PROMOTING PLANT GROWTH | Sumitomo Chemical Company Limited (JP) | 2015-10-07 | — | — | EP | disclosed |
| EP-2923574-A1 | METHOD FOR PROMOTING PLANT GROWTH | Sumitomo Chemical Company Limited (JP) | 2015-09-30 | — | — | EP | disclosed |
| EP-2923573-A1 | METHOD FOR PROMOTING PLANT GROWTH | Sumitomo Chemical Company Limited (JP) | 2015-09-30 | — | — | EP | disclosed |
| US-9139529-B2 | Substituted quinoxalines as sodium channel modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2616424-B1 | METHOD FOR PRODUCING 2-METHYL-3-(4-TERT-BUTYLPHENYL)-PROPANAL HAVING HIGH PARA-ISOMER PURITY | BASF SE (DE) | 2015-08-26 | — | — | EP | disclosed |
| EP-2616424-B1 | METHOD FOR PRODUCING 2-METHYL-3-(4-TERT-BUTYLPHENYL)-PROPANAL HAVING HIGH PARA-ISOMER PURITY | BASF SE (DE) | 2015-08-26 | — | — | EP | disclosed |
| US-20150218154-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2015-08-06 | — | — | US | disclosed |
| US-20150190390-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-07-09 | — | — | US | disclosed |
| US-9067931-B2 | 2-heteroaryl carboxamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-9018221-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD CALISTOGA, LLC (US) | 2015-04-28 | — | — | US | disclosed |
| US-9012473-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-21 | — | — | US | disclosed |
| US-20150065500-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-05 | — | — | US | disclosed |
| EP-2837617-A1 | Process for producing alicyclic aldehydes | Mitsubishi Gas Chemical Company Inc. (JP) | 2015-02-18 | — | — | EP | disclosed |
| US-8957093-B2 | N-biphenylmethylindole modulators of PPARG | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957093-B2 | N-biphenylmethylindole modulators of PPARG | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957093-B2 | N-biphenylmethylindole modulators of PPARG | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-02-17 | — | — | US | disclosed |
| EP-1510512-B1 | Process for producing alicyclic aldehydes | MITSUBISHI GAS CHEMICAL CO (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20140350008-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| US-20140343054-A1 | Therapeutic Use of Imidazopyridine Derivatives | SANOFI (FR) | 2014-11-20 | — | — | US | disclosed |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2014-11-06 | — | — | US | disclosed |
| EP-2796455-A1 | METHOD FOR PRODUCING SULFONATE | Sumitomo Chemical Co., Ltd (JP) | 2014-10-29 | — | — | EP | disclosed |
| CN-102365393-B | Electrochemical method for producing 3 tert.-butyl benzaldehyde- dimethylacetal | BASF SE (DE) | 2014-10-29 | — | — | CN | disclosed |
| US-20140303151-A9 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140256697-A1 | CEPHEM DERIVATIVE HAVING CATECHOL GROUP | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-20140243328-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-08-28 | — | — | US | disclosed |
| US-8815845-B2 | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140235642-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140228371-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140206689-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-24 | — | — | US | disclosed |
| US-8778941-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140179673-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2014-06-26 | — | — | US | disclosed |
| US-8759344-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-06-24 | — | — | US | disclosed |
| US-8741933-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-03 | — | — | US | disclosed |
| US-20140045825-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8642604-B2 | Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-04 | — | — | US | disclosed |
| US-8637542-B2 | Kinase inhibitors and methods of use | INTELLIKINE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8633160-B2 | Small molecule inhibitors of PDZ interactions | NONO INC. (CA) | 2014-01-21 | — | — | US | disclosed |
| US-8629304-B2 | Electrochemical method for producing 3-tert-butylbenzaldehyde dimethyl acetal | BASF SE (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8629304-B2 | Electrochemical method for producing 3-tert-butylbenzaldehyde dimethyl acetal | BASF SE (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8629304-B2 | Electrochemical method for producing 3-tert-butylbenzaldehyde dimethyl acetal | BASF SE (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8614358-B2 | Process for preparing 2-methyl-3-(4-tert-butylphenyl)propanal with high para-isomer purity | BASF SE (DE) | 2013-12-24 | — | — | US | disclosed |
| EP-1656345-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-10-16 | — | — | EP | disclosed |
| US-8558012-B2 | 2-fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivative, production method thereof, and production method of monofluoromethyl group-containing compound using the same | NAGOYA INSTITUTE OF TECHNOLOGY (JP) | 2013-10-15 | — | — | US | disclosed |
| US-8546414-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130245011-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-19 | — | — | US | disclosed |
| US-20130245010-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-19 | — | — | US | disclosed |
| US-20130237568-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-12 | — | — | US | disclosed |
| EP-2616424-A1 | METHOD FOR PRODUCING 2-METHYL-3-(4-TERT-BUTYLPHENYL)-PROPANAL HAVING HIGH PARA-ISOMER PURITY | BASF SE (DE) | 2013-07-24 | — | — | EP | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130158034-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| CN-103119014-A | Method for producing 2-methyl-3-(4-tert-butylphenyl)-propanal having high para-isomer purity | BASF SE | 2013-05-22 | — | — | CN | disclosed |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | disclosed |
| EP-2569055-A2 | PHOTO-STABILIZING AGENTS | Merck Patent GmbH (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-20130059924-A1 | PHOTOSTABILISERS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20130045952-A1 | ABA Receptor Agonists for Increased Plant Stress Resistance | VAN ANDEL RESEARCH INSTITUTE (US) | 2013-02-21 | — | — | US | disclosed |
| US-8367710-B2 | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2013-02-05 | — | — | US | disclosed |
| US-20130018040-A1 | Compositions And Methods For Treating Toxoplasmosis, Cryptosporidiosis, And Other Apicomplexan Protozoan Related Diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2013-01-17 | — | — | US | disclosed |
| EP-1979314-B1 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | LILLY CO ELI (US) | 2013-01-09 | — | — | EP | disclosed |
| WO-2012170554-A1 | N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG | KAMENECKA THEODORE MARK (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012170554-A1 | N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG | KAMENECKA THEODORE MARK (US) | 2012-12-13 | — | — | WO | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-20120309757-A1 | N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309757-A1 | N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309757-A1 | N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2012-12-06 | — | — | US | disclosed |
| US-8324207-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120270318-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270862-A1 | 1,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-25 | — | — | US | disclosed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120258964-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER SCHERING PHARMA AG (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-08-02 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
| US-20120071696-A1 | PROCESS FOR PREPARING 2-METHYL-3-(4-TERT-BUTYLPHENYL)PROPANAL WITH HIGH PARA-ISOMER PURITY | BASF SE (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071696-A1 | PROCESS FOR PREPARING 2-METHYL-3-(4-TERT-BUTYLPHENYL)PROPANAL WITH HIGH PARA-ISOMER PURITY | BASF SE (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071696-A1 | PROCESS FOR PREPARING 2-METHYL-3-(4-TERT-BUTYLPHENYL)PROPANAL WITH HIGH PARA-ISOMER PURITY | BASF SE (DE) | 2012-03-22 | — | — | US | disclosed |
| WO-2012034930-A1 | METHOD FOR PRODUCING 2-METHYL-3-(4-TERT-BUTYLPHENYL)-PROPANAL HAVING HIGH PARA-ISOMER PURITY | BASF SE (DE) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012034930-A1 | METHOD FOR PRODUCING 2-METHYL-3-(4-TERT-BUTYLPHENYL)-PROPANAL HAVING HIGH PARA-ISOMER PURITY | BASF SE (DE) | 2012-03-22 | — | — | WO | disclosed |
| CN-102365393-A | Electrochemical method for producing 3 tert.-butyl benzaldehyde- dimethylacetal | BASF SE | 2012-02-29 | — | — | CN | disclosed |
| EP-2411564-A1 | ELECTROCHEMICAL METHOD FOR PRODUCING 3 TERT.-BUTYL BENZALDEHYDE- DIMETHYLACETAL | BASF SE (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20120016162-A1 | ELECTROCHEMICAL METHOD FOR PRODUCING 3-TERT-BUTYLBENZALDEHYDE DIMETHYL ACETAL | BASF SE (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120016162-A1 | ELECTROCHEMICAL METHOD FOR PRODUCING 3-TERT-BUTYLBENZALDEHYDE DIMETHYL ACETAL | BASF SE (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120016162-A1 | ELECTROCHEMICAL METHOD FOR PRODUCING 3-TERT-BUTYLBENZALDEHYDE DIMETHYL ACETAL | BASF SE (DE) | 2012-01-19 | — | — | US | disclosed |
| WO-2012004732-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | WO | disclosed |
| US-8093406-B2 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG (CH) | 2012-01-10 | — | — | US | disclosed |
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20110319637-A1 | 2-FLUORO-1,3-BENZODITHIOL 1,1,3,3-TETRAOXIDE DERIVATIVE, PRODUCTION METHOD THEREOF, AND PRODUCTION METHOD OF MONOFLUOROMETHYL GROUP-CONTAINING COMPOUND USING THE SAME | NAGOYA INSTITUTE OF TECHNOLOGY (JP) | 2011-12-29 | — | — | US | disclosed |
| US-8084395-B2 | 4-aza indole derivatives and their use as fungicides | SYNGENTA CROP PROTECTION, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084395-B2 | 4-aza indole derivatives and their use as fungicides | SYNGENTA CROP PROTECTION, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110301144-A1 | Kinase Antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301144-A1 | Kinase Antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | US | disclosed |
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| WO-2011141110-A2 | PHOTO-STABILIZING AGENTS | MERCK PATENT GMBH (DE) | 2011-11-17 | — | — | WO | disclosed |
| US-20110269779-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OPHTHALMIC CONDITIONS | INTELLIKINE, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110263591-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER SCHERING PHARMA AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263591-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER SCHERING PHARMA AG (DE) | 2011-10-27 | — | — | US | disclosed |
| EP-1889826-B1 | METHOD FOR PRODUCING A HEXAHYDROFUROFURANOL DERIVATIVE | SUMITOMO CHEMICAL CO (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2011-09-15 | — | — | US | disclosed |
| WO-2011094628-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS. CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | UNIVERSITY OF WASHINGTON (US) | 2011-08-04 | — | — | WO | disclosed |
| US-7977485-B2 | 2-heteroaryl carboxamides | BAYER SCHERING PHARMA AKTIENGESELLSHAFT (DE) | 2011-07-12 | — | — | US | disclosed |
| US-7951977-B2 | Process for producing hexahydrofurofuranol derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-31 | — | — | US | disclosed |
| CN-102076678-A | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG | 2011-05-25 | — | — | CN | disclosed |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | Vertex Pharmaceuticals Incorported (US) | 2011-04-28 | — | — | US | disclosed |
| US-7932284-B2 | Indole sulfonamide modulators of progesterone receptors | ELI LILLY AND COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2303857-A1 | CYCLIC SULFONES WITH AMINOBENZYL SUBSTITUTION USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100316601-A1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2010-12-16 | — | — | US | disclosed |
| US-7851464-B2 | Spirolactam aryl CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7829571-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829571-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100261914-A1 | IAP BINDING COMPOUNDS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100256421-A1 | Propanal Production Methods | O'LAUGHLIN INDUSTRIES, CO. LTD. (CN) | 2010-10-07 | — | — | US | disclosed |
| WO-2010108874-A1 | ELECTROCHEMICAL METHOD FOR PRODUCING 3 TERT.-BUTYL BENZALDEHYDE- DIMETHYLACETAL | BASF SE (DE) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010108874-A1 | ELECTROCHEMICAL METHOD FOR PRODUCING 3 TERT.-BUTYL BENZALDEHYDE- DIMETHYLACETAL | BASF SE (DE) | 2010-09-30 | — | — | WO | disclosed |
| EP-2233556-A1 | Isomeric mixture of meta and para tertio-butylphenyl propanal and production thereof | O'Laughlin Industries, Co. Ltd. (HK) | 2010-09-29 | — | — | EP | disclosed |
| US-7803956-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-09-28 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100184598-A1 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20100184598-A1 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| US-7737154-B2 | CRF receptor antagonists and methods relating thereto | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2010-06-15 | — | — | US | disclosed |
| US-7737154-B2 | CRF receptor antagonists and methods relating thereto | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2010-06-15 | — | — | US | disclosed |
| EP-2190833-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | Novartis Ag (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-7718600-B2 | IAP binding compounds | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2010-05-18 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20100056490-A1 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056505-A1 | Substituted Pyrazalones | BIOGEN IDEC MA INC. | 2010-03-04 | — | — | US | disclosed |
| US-20100056505-A1 | Substituted Pyrazalones | BIOGEN IDEC MA INC. | 2010-03-04 | — | — | US | disclosed |
| US-7659412-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-02-09 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| WO-2010003976-A1 | CYCLIC SULFONES WITH AMINOBENZYL SUBSTITUTION USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2010-01-14 | — | — | WO | disclosed |
| US-20100009963-A1 | KINASE ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090292014-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-11-26 | — | — | US | disclosed |
| US-7622583-B2 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| WO-2009132453-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-11-05 | — | — | WO | disclosed |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED | 2009-10-08 | — | — | US | disclosed |
| US-20090247554-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247514-A1 | Spirolactam aryl cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2009-10-01 | — | — | US | disclosed |
| US-7589095-B2 | 4-phenyl-pyrimidine-2-carbonitrile derivatives | N.V. ORGANON (NL) | 2009-09-15 | — | — | US | disclosed |
| US-7589095-B2 | 4-phenyl-pyrimidine-2-carbonitrile derivatives | N.V. ORGANON (NL) | 2009-09-15 | — | — | US | disclosed |
| US-7585868-B2 | Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-09-08 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7572787-B2 | Substituted naphthalene sulfonamides | BIOVITRUM AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-7572787-B2 | Substituted naphthalene sulfonamides | BIOVITRUM AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20090176999-A1 | Process for producing hexahydrofurofuranol derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-07-09 | — | — | US | disclosed |
| US-20090124668-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-14 | — | — | US | disclosed |
| US-20090124668-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-14 | — | — | US | disclosed |
| US-7511063-B2 | High affinity quinoline-based kinase ligands | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| WO-2009038412-A2 | BETA-SECRETASE INHIBITING COMPOUNDS | LG LIFE SCIENCES, LTD. (KR) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009038411-A2 | BETA-SECRETASE INHIBITING COMPOUNDS HAVING OXO-DIHYDRO-PYRAZOLE MOIETY | LG LIFE SCIENCES, LTD. (KR) | 2009-03-26 | — | — | WO | disclosed |
| US-20090076088-A1 | Thrombin Receptor Antagonists | SCHERING CORPORATION | 2009-03-19 | — | — | US | disclosed |
| US-20090076088-A1 | Thrombin Receptor Antagonists | SCHERING CORPORATION | 2009-03-19 | — | — | US | disclosed |
| US-20090069383-A1 | Thrombin Receptor Antagonists | SCHERING CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-20090062213-A1 | Small Molecule Inhibitors of PDZ Interactions | ARBOR VITA CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-7498441-B2 | Biaryltetrahydroisoquinoline piperidines as selective MCH receptor antagonists for the treatment of obesity and related disorders | SCHERING CORPORATION (US) | 2009-03-03 | — | — | US | disclosed |
| WO-2009024615-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054427-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | BRIARD EMMANUELLE | 2009-02-26 | — | — | US | disclosed |
| US-7488742-B2 | Thrombin receptor antagonists | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7482335-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482335-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-01-22 | — | — | US | disclosed |
| US-20090005375-A1 | ACETYL COENZYME A CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20090005375-A1 | ACETYL COENZYME A CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080227684-A1 | Small Molecule Inhibitors of PDZ Interactions | NONO INC. (CA) | 2008-09-18 | — | — | US | disclosed |
| US-7420066-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1758870-B1 | 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | ORGANON NV (NL) | 2008-08-13 | — | — | EP | disclosed |
| US-20080114052-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080090813-A1 | 4-Phenyl-Pyrimidine-2-Carbonitrile Derivatives | Cai, Jiaqiang | 2008-04-17 | — | — | US | disclosed |
| US-20080090813-A1 | 4-Phenyl-Pyrimidine-2-Carbonitrile Derivatives | Cai, Jiaqiang | 2008-04-17 | — | — | US | disclosed |
| US-7338947-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB CO. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338947-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB CO. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
| EP-1889826-A1 | METHOD FOR PRODUCING HEXAHYDROFUROFURANOL DERIVATIVE | Sumitomo Chemical Company, Limited (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
| US-7291744-B2 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| EP-1780196-A2 | Pyridine derivatives for use as vanilloid receptor ligands | Amgen, Inc (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1780196-A2 | Pyridine derivatives for use as vanilloid receptor ligands | Amgen, Inc (US) | 2007-05-02 | — | — | EP | disclosed |
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | disclosed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | disclosed |
| EP-1764358-A2 | Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain | Amgen, Inc (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1764358-A2 | Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain | Amgen, Inc (US) | 2007-03-21 | — | — | EP | disclosed |
| US-7183270-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183270-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| US-20070032541-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT J | 2007-02-08 | — | — | US | disclosed |
| US-20070032541-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT J | 2007-02-08 | — | — | US | disclosed |
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CARTER PEROY H | 2007-02-08 | — | — | US | disclosed |
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CARTER PEROY H | 2007-02-08 | — | — | US | disclosed |
| US-20070032437-A1 | that bind cellular inhibitor of apoptosis proteins; drug design and development for diagnosis, prevention and treatment of cell proliferative disease; anticarcinogenic agents | THE TRUSTEES OF PRINCETON UNIVERSITY | 2007-02-08 | — | — | US | disclosed |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | disclosed |
| US-7163937-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| US-7163937-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-7071362-B2 | Process for producing alicyclic aldehydes | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20060030618-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-02-09 | — | — | US | disclosed |
| WO-2005121106-A1 | 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. ORGANON (NL) | 2005-12-22 | — | — | WO | disclosed |
| US-20050272931-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1463714-A4 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050227986-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-10-13 | — | — | US | disclosed |
| US-6906093-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-20050054879-A1 | Process for producing alicyclic aldehydes | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1510512-A1 | Process for producing alicyclic aldehydes | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1463714-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040152736-A1 | Thrombin receptor antagonists | TOPROL ACQUISITION LLC | 2004-08-05 | — | — | US | disclosed |
| US-6723883-B1 | REACTING A BENZALDEHYDE COMPOUND WITH AN ALKANALDEHYDE; CASCADE SYSTEM | BASF AKTIENGESELLSCHAFT (DE) | 2004-04-20 | — | — | US | disclosed |
| EP-1390336-A1 | METHOD FOR PRODUCING AROMATIC ALDEHYDES AND KETONES BY THE CATALYTIC OXIDATION OF ALKYL-AROMATIC COMPOUNDS | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2004-02-25 | — | — | EP | disclosed |
| EP-1220824-B1 | CONTINUOUS METHOD FOR PRODUCTION OF CINNAMALDEHYDE AND DIHYDROCINNAMALDEHYDE DERIVATIVES | BASF AG (DE) | 2004-02-11 | — | — | EP | disclosed |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003049702-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2002096849-A1 | METHOD FOR PRODUCING AROMATIC ALDEHYDES AND KETONES BY THE CATALYTIC OXIDATION OF ALKYL-AROMATIC COMPOUNDS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2002-12-05 | — | — | WO | disclosed |
| EP-1233014-A1 | ASYMMETRIC ORGANIC PEROXIDE, CROSSLINKING AGENT COMPRISING THE SAME, AND METHOD OF CROSSLINKING WITH THE SAME | NOF CORPORATION (JP) | 2002-08-21 | — | — | EP | disclosed |
| EP-1220824-A1 | CONTINUOUS METHOD FOR PRODUCTION OF CINNAMALDEHYDE AND DIHYDROCINNAMALDEHYDE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001027061-A1 | CONTINUOUS METHOD FOR PRODUCTION OF CINNAMALDEHYDE AND DIHYDROCINNAMALDEHYDE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-19 | — | — | WO | disclosed |
| US-5856334-A | ANTAGONIST FOR EOSINOPHILS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1999-01-05 | — | — | US | disclosed |
| EP-0773219-A1 | IMIDAZOQUINOLINE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-14 | — | — | EP | disclosed |
| US-5173509-A | Suramin and active analogues thereof in the treatment of hypercalcemia | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1992-12-22 | — | — | US | disclosed |
| JP-H02238097-A | PERFUME COMPOSITION | KURARAY CO LTD | 1990-09-20 | — | — | JP | disclosed |
| US-4431656-A | ANALGESICS; ANTIINFLAMMATORY AGENTS; ANTIPYRETICS; ANTICOAGULANTS | KANEGAFUCHI CHEMICAL INDUSTRY COMPANY LIMITED (JP) | 1984-02-14 | — | — | US | disclosed |
| EP-0045429-B1 | PROCESS FOR THE PREPARATION OF 4-TERT. BUTYLBENZALDEHYDES | BAYER AG (DE) | 1983-08-31 | — | — | EP | disclosed |
| EP-0045429-A2 | Process for the preparation of 4-tert. butylbenzaldehydes | BAYER AG (DE) | 1982-02-10 | — | — | EP | disclosed |
| US-4024273-A | Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity | SMITHKLINE CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-3947470-A | CORONARY VASODILATORS, TREATMENT OF ANGINA PECTORIS | SMITHKLINE CORPORATION (US) | 1976-03-30 | — | — | US | disclosed |
| US-3947470-A | CORONARY VASODILATORS, TREATMENT OF ANGINA PECTORIS | SMITHKLINE CORPORATION (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | MTOR, PI4KA, PIK3CA | ALDH1A1 4725/4885HDAC4 891/4885HDAC2 1387/4885 |
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | ALDH1A1 1402/4885HDAC4 2354/4885HDAC2 2239/4885 |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | ALDH1A1 2149/4885HDAC4 1384/4885HDAC2 1925/4885 |
| US-20210253565-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LIPC | ALDH1A1 292/4885HDAC4 680/4885HDAC2 210/4885 |
| US-20050272931-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ALDH1A1 3238/4885HDAC4 1064/4885HDAC2 892/4885 |
| US-20060030618-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ALDH1A1 3238/4885HDAC4 1064/4885HDAC2 892/4885 |
| US-20170042871-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | ALDH1A1 1773/4885HDAC4 1879/4885HDAC2 1694/4885 |
| US-20190241526-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | HSPA2, HSP90AA1, HSP90AB1 | ALDH1A1 511/4885HDAC4 2091/4885HDAC2 1634/4885 |
| US-20130018040-A1 | Compositions And Methods For Treating Toxoplasmosis, Cryptosporidiosis, And Other Apicomplexan Protozoan Related Diseases | PNCK, TXK, CILK1 | ALDH1A1 4776/4885HDAC4 2159/4885HDAC2 1375/4885 |
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LYN | ALDH1A1 4687/4885HDAC4 1733/4885HDAC2 938/4885 |
| US-11325930-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | ALDH1A1 2149/4885HDAC4 1384/4885HDAC2 1925/4885 |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | CYP11B2, CYP11B1, LTC4S | ALDH1A1 134/4885HDAC4 587/4885HDAC2 444/4885 |
| US-20090292014-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | PCNA, MKI67, CDK4 | ALDH1A1 609/4885HDAC4 1088/4885HDAC2 1925/4885 |
| US-20070066599-A1 | New compounds | SULT2A1, GPR119, STS | ALDH1A1 363/4885HDAC4 711/4885HDAC2 399/4885 |
| US-20090076088-A1 | Thrombin Receptor Antagonists | CNR1, CNR2, TBXA2R | ALDH1A1 3883/4885HDAC4 3411/4885HDAC2 2174/4885 |
| US-20080114052-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCL11, CCL2, CCR1 | ALDH1A1 1195/4885HDAC4 2752/4885HDAC2 2552/4885 |
| US-10316017-B2 | COT modulators and methods of use thereof | BRDT, THRB, HCCS | ALDH1A1 2149/4885HDAC4 1384/4885HDAC2 1925/4885 |
| US-11247972-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | PNCK, TXK, CILK1 | ALDH1A1 4776/4885HDAC4 2159/4885HDAC2 1375/4885 |
| US-20140243328-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CCNY, ENY2, PAH | ALDH1A1 2306/4885HDAC4 493/4885HDAC2 231/4885 |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | ALDH1A1 4730/4885HDAC4 1912/4885HDAC2 1111/4885 |
| US-11834424-B2 | Compounds useful as chaperone-mediated autophagy modulators | SQSTM1, HSPA5, ATG7 | ALDH1A1 2631/4885HDAC4 1294/4885HDAC2 1374/4885 |
| US-20170107205-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 1786/4885HDAC4 2944/4885HDAC2 3419/4885 |
| US-20130158034-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | ALDH1A1 4051/4885HDAC4 1660/4885HDAC2 1714/4885 |
| US-11974987-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | LIPC, LPL, MGLL | ALDH1A1 266/4885HDAC4 1024/4885HDAC2 522/4885 |
| US-20130245010-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 1991/4885HDAC4 2697/4885HDAC2 3157/4885 |
| US-20100056505-A1 | Substituted Pyrazalones | ACVR1, ACVRL1, TGFBR1 | ALDH1A1 507/4885HDAC4 678/4885HDAC2 2617/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | ALDH1A1 4709/4885HDAC4 2987/4885HDAC2 1773/4885 |
| US-20110319637-A1 | 2-FLUORO-1,3-BENZODITHIOL 1,1,3,3-TETRAOXIDE DERIVATIVE, PRODUCTION METHOD THEREOF, AND PRODUCTION METHOD OF MONOFLUOROMETHYL GROUP-CONTAINING COMPOUND USING THE SAME | CBR1, CYP1B1, CYP2F1 | ALDH1A1 160/4885HDAC4 2865/4885HDAC2 1510/4885 |
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | ALDH1A1 3621/4885HDAC4 1404/4885HDAC2 518/4885 |
| US-20240299365-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | LIPC, LPL, MGLL | ALDH1A1 266/4885HDAC4 1024/4885HDAC2 522/4885 |
| US-20150190390-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 1836/4885HDAC4 2980/4885HDAC2 3461/4885 |
| US-20100316601-A1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | THPO, MPL, TEK | ALDH1A1 1911/4885HDAC4 4216/4885HDAC2 3831/4885 |
| US-20090062213-A1 | Small Molecule Inhibitors of PDZ Interactions | PDLIM5, DAB2IP, PSD | ALDH1A1 4365/4885HDAC4 3373/4885HDAC2 3646/4885 |
| US-20220304307-A1 | SYNERGISTIC MIXTURES FOR ARTHROPOD TOXICITY AND REPELLENCY | DDT, L3MBTL3, L3MBTL4 | ALDH1A1 366/4885HDAC4 1213/4885HDAC2 424/4885 |
| US-20140350008-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | ALDH1A1 2755/4885HDAC4 1432/4885HDAC2 209/4885 |
| US-10675358-B2 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | ALDH1A1 978/4885HDAC4 2845/4885HDAC2 3800/4885 |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ALDH1A1 3105/4885HDAC4 1145/4885HDAC2 846/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALDH1A1 2353/4885HDAC4 163/4885HDAC2 136/4885 |
| US-20070066598-A1 | Compounds | SULT2A1, STS, SLC5A2 | ALDH1A1 262/4885HDAC4 955/4885HDAC2 374/4885 |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | ALDH1A1 4687/4885HDAC4 1733/4885HDAC2 938/4885 |
| US-20140343054-A1 | Therapeutic Use of Imidazopyridine Derivatives | CCNY, UTS2R, WNK2 | ALDH1A1 2378/4885HDAC4 100/4885HDAC2 116/4885 |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | CRHR1, CRHR2, CRH | ALDH1A1 1525/4885HDAC4 3257/4885HDAC2 2487/4885 |
| US-11708359-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, LIPC | ALDH1A1 292/4885HDAC4 680/4885HDAC2 210/4885 |
| US-20140303151-A9 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | PIK3CD, PIK3CA, PIK3R5 | ALDH1A1 3321/4885HDAC4 2526/4885HDAC2 2017/4885 |
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AGTR1, AGTR2, APLNR | ALDH1A1 2364/4885HDAC4 2424/4885HDAC2 2170/4885 |
| US-20150218154-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, PIK3R5, PIK3R4 | ALDH1A1 3910/4885HDAC4 1752/4885HDAC2 852/4885 |
| US-20170226131-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | PIK3CD, PIK3CA, PIK3R5 | ALDH1A1 3183/4885HDAC4 2469/4885HDAC2 1982/4885 |
| US-20100256421-A1 | Propanal Production Methods | ALDH2, ALDH1A3, TERT | ALDH1A1 4/4885HDAC4 3034/4885HDAC2 1907/4885 |
| US-20230117611-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | LIPC, LPL, MGLL | ALDH1A1 266/4885HDAC4 1024/4885HDAC2 522/4885 |
| US-20180099931-A1 | Substituted Pyrrolidines and Methods of Use | CFTR, PKD1, PKD2 | ALDH1A1 586/4885HDAC4 3187/4885HDAC2 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.